We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Bacterium Actively Drives CRC Tumor Growth

By LabMedica International staff writers
Posted on 27 Jul 2017
Colorectal cancer (CRC) is a leading cause of cancer-related death. More...
The recognition that microbial agents can contribute to the development of CRC raises hope for improving CRC diagnosis and treatment by incorporating both microbial and patient characteristics into clinical strategies.

It has been known for some time that people infected with the Streptococcus gallolyticus subspecies gallolyticus (Sgg) are more likely to have colorectal cancer (CRC), and is the second most common cause of cancer in women. However, it was unknown whether Sgg actively promotes CRC or whether it simply grows comfortably in the environment provided by CRC tumor cells.

Scientists at Texas A&M Health Science Center (Houston, TX, USA) and colleagues performed several studies using cultured human colorectal cells, mice with CRC, and tissue from human tumors. They used various techniques including using cultured bacterial cell lines, human colon cancer cell lines, cell proliferation assays, adherence and internalization assays, Western blot assays. They also performed quantitative reverse transcription polymerase chain reaction (RT-qPCR) to compare relative expression of cyclin D1 and cytokines in a Viia 7 Real Time PCR System. Flow cytometry analysis of samples was done using a LSRII flow cytometer.

The investigators demonstrated that Sgg promotes human colon cancer cell proliferation in a manner that depends on cell context, bacterial growth phase and direct contact between bacteria and colon cancer cells. In addition, they observed increased level of β-catenin, c-Myc and proliferating cell nuclear antigen (PCNA) in colon cancer cells following incubation with Sgg. The team tested tumor samples from people with colon cancer, they found 74% had Sgg bacteria in them, and 26% had very high levels of it. They also showed that Sgg is present in the majority of CRC patients and is preferentially associated with tumor compared to normal tissues obtained from CRC patients.

The authors concluded that overall, their findings strongly suggest that Sgg plays an active role in CRC development in humans. In the future, the precise mechanisms of its tumor-promoting activity could potentially be exploited to develop new strategies to diagnose, prevent, and treat CRC. The study was published on July 13, 2017, in the journal Public Library of Science Pathogens.

Related Links:
Texas A&M Health Science Center


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Gold Member
POCT RT-qPCR Analyzer
BG-X6
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: iStock

Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain

Chest pain leads to ambulance transport to an emergency department for about 95% of patients, although only a minority have a serious cardiac condition. Troponin testing helps assess heart muscle damage,... Read more

Molecular Diagnostics

view channel
Image: Graphical Abstract (Image Credit: Cheng N, Ouellette TW, Skead K, et al. Pre-diagnosis plasma cell-free DNA reveals early signatures of prostate and breast cancer risk up to eight years prior to clinical detection. Cell Genomics (2026). DOI:10.1016/j.xgen.2026.101364)

Blood Test Stratifies Prostate and Breast Cancer Risk Years Before Diagnosis

Cancer is the second leading cause of death globally, and late diagnosis contributes substantially to mortality. Routine screening is available for only a few cancer types, while other early detection... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: RealTime Labs’ Mycotoxin Extensive Panel measures 31 mold-related toxins across seven toxin classes from a single urine sample (Photo courtesy of RealTime Labs)

New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment

Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Collaboration combines cognitive assessment, blood testing, phlebotomy, and MRI to support faster diagnosis across the UK (Image Credt: Adobe Stock)

New UK Collaboration Expands Access to Integrated Alzheimer’s Diagnostic Testing

C2N Diagnostics and Cambridge Cognition have partnered with The Alzheimer’s Trust to create an integrated pathway aimed at supporting earlier and more accurate diagnosis of Alzheimer’s disease and related dementias.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.